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Most of the early negative randomized trials of HDC in BC
studied the single-cycle late-intensiﬁcation approach, following
conventional induction therapy. Crown and Norton (Sem Oncol
1995) hypothesized that “induction” CDC might make little cy-
toreductive contribution to a strategy which includes HDC, and
that multiple densely sequenced cycles of HDC might be prefer-
able. In the International Randomized Breast Cancer Dose-Inten-
sity Study (IBDIS-I), patients received a brief phase of CDC
induction, followed by tandem cycles of autograft-supported high-
dose therapy (HDC), or, CDC alone, in chemotherapy-naı¨ve
MBC. Accrual failed in the aftermath of the Bezwoda disclosures,
and only 110 of a planned 264 patients were enrolled. Results:
There were 7 treatment deaths (2-CDC; 5-HDC). Complete and
overall response rates (CR/OR) were signiﬁcantly superior for
HDC v CDC (CR-29% v 6%, OR-71% v 44%). Event-free-
survival at 3 yrs was: HDC 16% versus CDC 9% (p  .0149).
Currently, at a median (med) follow-up of 47 months (range
70-24), 14% of HDC and 7% of CDC pts remain event-free (34%
versus 26% alive, 21% v 11% progression-free). The med duration
of EFS (and OS) were: HDC 428 (961) and CDC 291 (795) days
(EFS: p  0.019, and for survival: p  0.14). Progression–free
survivals were: HDC 439, CDC 322 days (p  .0096). Although
these data appear to conﬂict with the results of other studies, there
were critical design differences between IBDIS and most of the
other trials, which usually applied single high-dose cycles, often
many months after the start of conventional chemotherapy for
metastasis, as “late intensiﬁcation” for patients in ongoing response
to prior CDC. Conclusion: HDC remains a valid investigational
strategy for MBC. The recent report of a second positive “mini-
mum induction/tandem transplant” trial by Nitz et al (ASCO
2003) suggests that the breast oncology and transplant communi-
ties should come together to perform a deﬁnitive investigation of
primary multi-cycle HDC, rather than initiating further studies of
“traditional” single-cycle, late-intensiﬁcation HDC. This approach
will be tested in IBDIS-II.
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ALDEHYDE DEHYDROGENASE [ALDH] AND SURFACE ANTIGEN EX-
PRESSION DEFINE HEMATOPOEITIC STEM AND PROGENITOR CELL
[HSPC] SUBSETS DIFFERENTIALLY REPRESENTED IN MOBILIZED PE-
RIPHERAL BLOOD [PBSC], UMBILICAL CORD BLOOD [UCB], AND
BONE MARROW [BM]
Gentry, T., Winstead, L., Deibert, E., Fiordalisi, M., Foster, S.J.,
Pritchard, C., Balber, A.E. STEMCO Biomedical, Inc., Durham, NC
Flow cytometric analysis of ALDH activity identiﬁes HSPC in
UCB, PBSC, and BM as ALDH-bright, side scatter low [ALDHbr-
SSclow] populations. We used a panel of 21 monoclonal antibodies to
compare the immunophenotypes of cells in ALDHbr-SSclow popu-
lations in each type of graft material. BM was obtained from normal
donors; PBSC, from cancer patients or normal donors. UCB samples
were processed with hetastarch or hetastarch and ﬁcoll. Fresh samples
were analyzed after erythrocyte lysis by methods optimized for each
graft type. ALDHbr-SSclow cells comprised 0.5-1.1% of the total
nucleated cells. We collected immunophenotype data from 3000
gated ALDHbr-SSclow cells per sample. In all three graft types,
90% of the ALDHbr-SSclow cells expressed no lineage marker
characteristic of mature lymphocytes, NK cells, monocytes, or devel-
oping erythrocytes. However, the ALDHbr-SSclow population in
each graft type was composed of different proportions of cells express-
ing surface markers associated with HSPC function. First, the pro-
portion of primitive CD34CD38-cells in the ALDHbr-SSclow
population was considerably higher, and expression of the myeloid
lineage markers CD13 and CD33 was lower, in UCB than in PBSC
or BM. Second, the ALDHbr-SSclow population in UCB, but not in
PBSC or BM populations, included about four times more CD7
cells than CD3 cells, suggesting that CD7 lymphoid progenitors
are enriched in the UCB population. Third, BM ALDHbr-SSclow
cells were enriched about 50-fold for CD105, a marker associated
with hematopoeitic and non-hematpoietic stem cell functions, and
about 2-fold for both stem cell growth factor receptor CD117 and the
early differentiation marker CD41 relative to populations from PBSC
and UCB. Finally, cells expressing CD133 were about 2.5 times more
frequent in PBSC than in BM or UCB. The proportion of the total
population of cells expressing a given surface marker that also had the
ALDHbr-SSclow phenotype varied from 88.5% of the CD34 cells
in PBSC to 1.2% of CD90 cells in UCB. In some cases, the
proportion of cells expressing a given marker that also ALDHbr-
SSclow was different in different graft types. For example, 64.1% of
the CD105 cells in BM, but 0.5% of the CD105 cells in UCB and
PBSC, were ALDHbr-SSclow. Thus, ALDH expression and surface
antigen expression together deﬁne new stem/progenitor cell subsets
that are differentially represented in the three types of hematopoeitic
graft material we analyzed.
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PREVENTION OF CYTOMEGALOVIRUS (CMV) REACTIVATION BY STAN-
DARD DOSE VALACYCLOVIR (VACV) AFTER ALLOGENEIC BONE MAR-
ROW TRANSPLANTATION
Mori, T., Shimizu, T., Aisa, Y., Ikeda, Y., Okamoto, S. Division of
Hematology, Keio Univ. School of Medicine, Tokyo, Japan
In spite of the advances in the strategies against CMV reactiva-
tion and subsequent disease, including preemptive or prophylactic
administration of ganciclovir, CMV disease causes signiﬁcant mor-
bidity and mortality in high-risk patients undergoing allogeneic
hematopoietic stem cell transplantation (HSCT). Although ganci-
clovir is highly effective against CMV, its myelotoxicity is associ-
ated with secondary infection and reduced survival. In contrast,
acyclovir and its prodrug VACV have a more favorable safety
proﬁle. A recent study showed a signiﬁcant reduction in the inci-
dence of CMV reactivation after allogeneic HSCT with high-dose
VACV (8000 mg/day) as compared with acyclovir (Ljungman P, et
al, 2002). We have examined an efﬁcacy of standard dose VACV in
the prevention of CMV reactivation after allogeneic bone marrow
transplantation (BMT). Twelve CMV seropositive recipients
and/or donor subjects, who underwent allogeneic BMT from an
HLA-matched unrelated donor, were enrolled. Patients were con-
ditioned with TBI- or busulfan-based myeloablative conditioning
regimens. Patients received i.v. acyclovir (750 mg/dody/day) from
day-3 until patients became capable of taking oral VACV. VACV
was initiated at a dose of 3000 mg/day and continued until day 100.
CMV reactivation was monitored by CMV antigenemia assay and
real-time PCR using plasma. Thirty-ﬁve patients undergoing un-
related BMT without any prophylactic therapy against CMV were
used as a comparable control. CMV reactivation was detected in 4
of 12 patients (33%) as compared with 24 of 35 (68.6%) in a
control (P0.05). Among the 4 patients with CMV reactivation, 2
preemptively received ganciclovir, while CMV reactivation became
undetectable with VACV alone in the 2 remaining patients. No
case developed CMV disease, while 14% developed CMV disease
in a control (not signiﬁcant). Adverse events probably due to
VACV include nausea in 2 patients, and thromobocytopenia in 2
patients. These data strongly suggested that standard dose VACV
could safely and effectively prevent CMV reactivation in high-risk
patients undergoing allogeneic HSCT.
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